Skip to main content
Top

Risks and Prognostic Implications of Pericardial Disease and Atrial Fibrillation after Cardiac Surgery

  • 01-12-2025
  • Heart Surgery
  • Pericardial Disease (AL Klein and CL Jellis, Section Editors)
Published in:

Abstract

Purpose of Review

Postoperative atrial fibrillation (POAF) and post pericardiotomy syndrome (PPS) are among the most common complications following cardiac surgery. This review explores their incidence, clinical features, risk factors, and shared inflammatory mechanisms. It also examines prevention and management strategies, with a focus on the relationship between PPS and POAF and remaining gaps in understanding.

Recent Findings

Pericardial inflammation and innate immune activation are central to the development of both POAF and PPS. Surgical trauma initiates cascades involving cytokines, oxidative stress, and atrial remodeling. PPS has been associated with a higher risk of atrial fibrillation in the early postoperative period. Although current prediction models do not provide optimal discrimination, several preventive strategies, including preoperative medications and surgical options, have been shown to reduce the risk of these complications. However, varying definitions and diagnostic criteria limit comparability across studies, and long-term data are scarce.

Summary

POAF and PPS are associated with significant morbidity, including longer hospital stays, readmissions, and cardiovascular complications. Identifying high-risk patients is essential to guide early interventions. The overlap in pathophysiology suggests PPS may trigger POAF, but causality remains unconfirmed. Future research should focus on clarifying their relationship, assessing the durability of preventive strategies, and establishing standardized diagnostic criteria to reduce heterogeneity and improve clinical decision-making.
Title
Risks and Prognostic Implications of Pericardial Disease and Atrial Fibrillation after Cardiac Surgery
Authors
Lamis El Harake
Mohamed Al-Kazaz
Paul C. Cremer
Publication date
01-12-2025
Publisher
Springer US
Published in
Current Cardiology Reports / Issue 1/2025
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-025-02303-x
This content is only visible if you are logged in and have the appropriate permissions.

Next-generation MRI contrast agents: preparing the field (Link opens in a new window)

New MRI contrast agents are reshaping diagnostic imaging, promising lower gadolinium exposure amid evolving practice guidelines. How can you optimise contrast selection, dosing, and patient care in this rapidly advancing field?

This content is intended for healthcare professionals outside of the UK.

Independent Medical Education Grant:
  • Bayer HealthCare Pharmaceuticals Inc.
Learn more Link opens in a new window
Image Credits
Abstract graphic of layered, concentric circular shapes in bright green, pink, blue, and purple on a dark blue background. The rings and segments form a complex radial pattern without text/© Springer Health+ IME